✦ LIBER ✦

Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients

✍ Scribed by Michel de Bandt, Bruno Fautrel, Jean Francis Maillefert…

Book ID: 120706934
Publisher: BioMed Central
Year: 2009
Tongue: English
Weight: 249 KB
Volume: 11
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar2836

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of tocilizumab in patients with

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

✍ Yazici, Y.; Curtis, J. R.; Ince, A.; Baraf, H.; Malamet, R. L.; Teng, L. L.; Kav 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 301 KB

Low-dose prednisolone in addition to the

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial

✍ Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 2 views

## Abstract ## Objective To assess the efficacy of low‐dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). ## Methods At the start of their initial treatment with a disease‐modifying antirheumatic drug (DMARD), patients with early (duration ≤1